NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68001-0615-36 | 68001-0615 | MITOMYCIN | MITOMYCIN | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | July 8, 2024 | In Use | |
68001-0616-77 | 68001-0616 | MITOMYCIN | MITOMYCIN | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | June 24, 2024 | In Use | |
68001-0617-79 | 68001-0617 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | July 11, 2024 | In Use | |
68001-0618-37 | 68001-0618 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 3, 2024 | In Use | |
68083-0592-01 | 68083-0592 | Eribulin mesylate | Eribulin mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | April 5, 2024 | In Use | |
68475-0509-01 | 68475-0509 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | June 8, 2022 | In Use | |
70748-0339-01 | 70748-0339 | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 1, 2024 | In Use | |
70748-0340-01 | 70748-0340 | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 1, 2024 | In Use | |
71288-0174-21 | 71288-0174 | Dacarbazine | Dacarbazine | 200.0 mg/20mL | Chemotherapy | Alkylating Agent | Purine Analog | Intravenous | April 22, 2024 | In Use | |
72338-0200-01 | 72338-0200 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | June 19, 2018 | In Use | |
75907-0191-02 | 75907-0191 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | June 20, 2024 | In Use | |
72603-0320-01 | 72603-0320 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 11, 2024 | In Use | |
72603-0420-01 | 72603-0420 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 11, 2024 | In Use | |
75907-0112-11 | 75907-0112 | Melphalan Hydrochloride | Melphalan Hydrochloride | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | June 26, 2024 | In Use | |
75907-0189-35 | 75907-0189 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | June 20, 2024 | In Use | |
75907-0190-07 | 75907-0190 | cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | June 20, 2024 | In Use | |
81298-3890-01 | 81298-3890 | Eribulin Mesylate | Eribulin Mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | July 22, 2024 | In Use | |
83703-0532-01 | 83703-0532 | Bortezomib | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
83703-0533-01 | 83703-0533 | Bendamustine hydrochloride | BENDAMUSTINE HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 15, 2022 | In Use | |
83703-0561-01 | 83703-0561 | PEMETREXED | PEMETREXED | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Aug. 18, 2022 | In Use | |
83774-0102-01 | 83774-0102 | Azacitidine | AZACITIDINE | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | March 14, 2024 | In Use | |
83831-0101-02 | 83831-0101 | Docetaxel | DOCIVYX | 20.0 mg/2mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 9, 2024 | In Use | |
83831-0102-08 | 83831-0102 | Docetaxel | DOCIVYX | 80.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 9, 2024 | In Use | |
83831-0103-16 | 83831-0103 | Docetaxel | DOCIVYX | 160.0 mg/16mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 9, 2024 | In Use | |
83831-0105-01 | 83831-0105 | Palonosetron | Posfrea | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | July 30, 2024 | In Use |
Found 10,000 results in 5 milliseconds — Export these results